



## Supplementary Figures and Legends:

### Suppl. Fig. 1.




**Supplementary Figure 1. EpCAM aptamer penetrates tumorsphere more effectively than the EpCAM antibody.** EpCAM aptamer, control aptamer, or EpCAM antibody of the same concentration (100 nM) were incubated with HT29 tumorsphere for up to 240 min at 37 °C. The tumorspheres were then washed three times in PBS and imaged using laser scanning confocal microscopy. The images of the middle z-stack sections (marked by yellow lines) were used for the comparison of tumorsphere penetration. Scale bar: 200  $\mu$ m.

Suppl. Fig. 2.



**Supplementary Figure 2. EpCAM aptamer is retained much longer inside tumorsphere than the EpCAM antibody.** EpCAM aptamer, control aptamer, or EpCAM antibody of the same concentration (100 nM) were incubated with Huh-7 tumorsphere for up to 240 min at 37 °C. The tumorspheres were then washed three times in PBS and either imaged using laser scanning confocal microscopy or incubated for further 4 h and 24 h incubation in phenol red-free culture medium. Scale bar: 200  $\mu$ m.

Suppl. Fig. 3.



**Supplementary Figure 3. Modification of EpCAM aptamers exhibits a desirable *in vitro* stability.** (a) 5  $\mu$ M of free EpCAM aptamer and PEGylated aptamer were incubated in 50 % fetal bovine serum (FBS) (V:V = 1:1) for up to 48 hours. Aptamers in serum-aptamer mixtures at the indicated time-points (0, 0.25, 0.5, 1, 2, 3, 4, 24, and 48 hours) were recovered using phenol-chloroform extraction and the full-length aptamer were resolved on a 2.5% agarose gel. (b) The remaining full-length aptamers at each time points were quantified using a LAS-4000 Imaging System (GE Healthcare Life Sciences). Data shown are means  $\pm$  SEM, n=3.